Merck (MRK) Declares $0.48 Quarterly Dividend; 3% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Merck (MRK) Reports Phase 3 KEYNOTE-048 Trial Investigating KEYTRUDA (pembrolizumab) Anti-PD-1 Therapy Met Primary Endpoint of OS
July 25, 2018 5:58 AM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA® (pembrolizumab), Mercks anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), met a primary endpoint of overall survival (OS) as monotherapy in patients whose tumors expressed PD-L1 (Combined Proportion Score (CPS) 20). Based on an interim analysis conducted by the independent Data Monitoring Committee (DMC), treatment with KEYTRUDA monotherapy in these patients resulted in significantly longer OS compared to cetuximab in combination with platinum chemotherapy (cisplatin or... More
Merck (MRK) Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
July 24, 2018 6:51 AM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical trial evaluating the efficacy and safety of doravirine (DOR), the companys investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history (treatment-naïve). At Week 96, 73.1 percent (277/379) of the group treated with once-daily DOR achieved viral suppression as measured by the proportion of patients who achieved HIV-1 RNA of less than 50 copies/mL, compared to 66.0 percent (248/376)... More
Investors are Underappreciating Merck's (MRK) Revenue and Profit Growth - Morgan Stanley
July 23, 2018 8:46 AM EDTMorgan Stanley analyst David Risinger believes many investors are underappreciating Merck's (NYSE: MRK) accelerating revenue and profit growth starting in 2019 driven by 1) diminishing declines in certain franchises (Vytorin/Zetia, Zepatier, and Zostavax) and 2) strong performance of growth franchises such as Keytruda and... More
